The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Figures

• 

  FIGURE 1. Cardiorenal outcomes by baseline blood pressure (BP) category, adjusted for baseline variables related to cardiorenal risk, in the LEADER (A) and SUSTAIN 6 trials (B). †Primary major adverse cardiovascular events (MACE): composite of cardiovascular death, non‐fatal myocardial infarction (MI) and non‐fatal stroke. Analysis adjusted for baseline characteristics related to cardiorenal risk (age, antihyperglycaemic medications, diabetes duration, geographic region, history of MI or stroke, renal function as measured by estimated glomerular filtration rate, sex, and smoking status). ‡Nephropathy (new or worsening): new or persistent macroalbuminuria, doubling of serum creatinine, end‐stage kidney disease or death from kidney disease. §Analysis adjusted as for MACE, with the omission of smoking status because of a low number of events. BP categories were defined as follows: normal = systolic blood pressure (SBP) < 120 mmHg, diastolic blood pressure (DBP) 80 mmHg; elevated = SBP 120‐129 mmHg and DBP < 80 mmHg; stage 1 hypertension = SBP 130‐139 mmHg or DBP 80‐89 mmHg; stage 2 hypertension = SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. CI, confidence interval; HR, hazard ratio

• 

  FIGURE 2. Quadratic spline regression treatment differences in time to first major adverse cardiovascular events (MACE), according to baseline systolic blood pressure (SBP) (A and B) and diastolic blood pressure (DBP) (C and D), in the LEADER (A and C) and SUSTAIN 6 (B and D) trials. Primary MACE: composite of cardiovascular death, non‐fatal myocardial infarction (MI) and non‐fatal stroke. Q1, one quarter of patients had a lower blood pressure (BP) value than this. Median, half of patients had a lower BP value than this. Q3, three‐quarters of patients had a lower BP value than this. BP categories were defined as follows: normal = SBP < 120 mmHg, DBP 80 mmHg; elevated = SBP 120‐129 mmHg and DBP < 80 mmHg; stage 1 hypertension = SBP 130‐139 mmHg or DBP 80‐89 mmHg; stage 2 hypertension = SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. LCL, lower confidence limit; Q, quartile; St., stage; UCL, upper confidence limit